临床采用维奈克拉联合阿扎胞苷治疗老年复发性急性髓系白血病的预后情况评估分析  

The Prognosis of Venetoclax Combined with Azacitidine in the Treatment of Elderly Recurrent Acute Myeloid Leukemia was Evaluated and Analyzed

作　　者：赵帅 李文[2] 王晓霞 胡坤鹏 王超 贾丽 ZHAO Shuai;LI Wen;WANG Xiaoxia;HU Kunpeng;WANG Chao;JIA Li(Department of Hematology and Oncology,Tai’an 88 Hospital,Tai’an,Shandong 271001,China;Department of Hematology,Tengzhou Central People’s Hospital,Zaozhuang,Shandong 277500,China;Department of Internal Medicine,Tengzhou Hospital of Traditional Chinese Medicine,Zaozhuang,Shandong 277500,China;Department of Oncology and Hematology,Tai’an First People’s Hospital,Tai’an,Shandong 271001,China)

机构地区：[1]泰安八十八医院血液肿瘤一科,山东泰安271001 [2]滕州市中心人民医院血液内科,山东枣庄277500 [3]滕州市中医医院内科,山东枣庄277500 [4]泰安市第一人民医院肿瘤血液科,山东泰安271001

出　　处：《中国医药指南》2025年第11期41-44,共4页Guide of China Medicine

摘　　要：目的研讨维奈克拉联合阿扎胞苷的疗效情况,分析单一及联合用药对老年复发性急性髓系白血病的预后价值。方法选取2022年8月至2024年8月泰安八十八医院、滕州市中心人民医院、泰安市第一医院收治的60例老年复发性急性髓系白血病患者,经随机数字表法确立组别,对照组(30例)给予阿扎胞苷治疗,研究组(30例)进行维奈克拉联合阿扎胞苷治疗。比较两组血液学指标改善、免疫功能指标、治疗有效率、血清炎性指标,并计算不良反应发生率。结果两组血液学指标状况均得到有效改善,且研究组骨髓原始细胞比例更低,血红蛋白浓度、血小板计数、白细胞计数更高(P<0.05)。两组CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)免疫功能指标均得到有效改善,且治疗后组间差异显示研究组更佳(P<0.05)。研究组治疗有效率高于对照组(P<0.05)。研究组TNF-α、IFN-γ血清炎性指标较对照组更高(P<0.05)。研究组不良反应发生率低于对照组(P<0.05)。结论维奈克拉联合阿扎胞苷对患者血液学指标的改善有积极意义,可以提升机体免疫功能,且不良反应发生率较低,利于疾病转归。Objective To study the efficacy of Vinecra combined with azacytidine,and to analyze the prognostic value of single and combined administration in elderly patients with relapsed acute myeloid leukemia.Methods A total of 60 elderly patients with recurrent acute myeloid leukemia treated at Tai’an Baishibayi Hospital,Tengzhou Central People’s Hospital,and Tai’an First People’s Hospital from August 2022 to August 2024 were divided into two groups according to the random number table method.The control group(30 cases)received azacitidine treatment,while the study group(30 cases)received venetoclax combined with azacitidine treatment.The study compared the two groups in terms of improvement in hematological indicators,immune function indicators,treatment efficacy rate,serum inflammatory indicators,and calculated the incidence of adverse reactions.Results The hematological indicators of both groups were effectively improved,with the study group showing a lower proportion of bone marrow blasts and higher levels of hemoglobin concentration,platelet count,and white blood cell count(P<0.05).The immune function indicators(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))of both groups were also effectively improved,and the study group showed better results after treatment compared to the control group(P<0.05).The treatment efficacy rate was higher in the study group than in the control group(P<0.05).The study group had higher levels of serum inflammatory indicators TNF-αand IFN-γcompared to the control group(P<0.05).The incidence of adverse reactions was lower in the study group than in the control group(P<0.05).Conclusions Venekra combined with azacytidine has positive significance in improving hematological indexes of patients,and can enhance the immune function of the body,and the incidence of adverse reactions is.

关 键 词：复发性急性髓系白血病 老年 维奈克拉 阿扎胞苷 血液学指标 免疫功能指标 

分 类 号：R733.71[医药卫生—肿瘤]